Healthcare [ 10/13 ] | Health Information Services [ 128/160 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | -0.41 Decreased by -7.89% | -0.38 Decreased by -7.89% |
| Nov 1, 23 | -0.86 Decreased by -53.57% | -0.71 Decreased by -21.13% |
| Aug 2, 23 | 0.06 Increased by +108.96% | -0.47 Increased by +112.77% |
| May 4, 23 | 1.75 Increased by +464.58% | 1.31 Increased by +33.59% |
| Feb 28, 23 | -0.38 Increased by +11.63% | -0.53 Increased by +28.3% |
| Nov 3, 22 | -0.56 Decreased by -14.29% | -0.65 Increased by +13.85% |
| Aug 4, 22 | -0.67 Decreased by -36.73% | -0.61 Decreased by -9.84% |
| May 4, 22 | -0.48 Decreased by -119.9 K% | -0.52 Increased by +7.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 42.57 M Increased by +15.11% | -62.02 M Decreased by -55.62% | Decreased by -145.7% Decreased by -35.19% |
| Jun 30, 23 | 35.19 M Decreased by -8.53% | 4.28 M Increased by +108.97% | Increased by +12.16% Increased by +109.81% |
| Mar 31, 23 | 64.78 M Increased by +33.12% | 129.14 M Increased by +474.84% | Increased by +199.34% Increased by +381.57% |
| Dec 31, 22 | 56.84 M Increased by +23.12% | -27.21 M Increased by +11.41% | Decreased by -47.87% Increased by +28.05% |
| Sep 30, 22 | 36.98 M Increased by +23.89% | -39.86 M Decreased by -13.85% | Decreased by -107.78% Increased by +8.1% |
| Jun 30, 22 | 38.47 M Increased by +29.16% | -47.67 M Decreased by -37.61% | Decreased by -123.93% Decreased by -6.54% |
| Mar 31, 22 | 48.66 M Increased by +51.47% | -34.45 M Decreased by -118.7 K% | Decreased by -70.8% Decreased by -78.33 K% |
| Dec 31, 21 | 46.17 M Increased by +39.77% | -30.71 M Decreased by -175.72% | Decreased by -66.52% Decreased by -97.27% |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.